CENTEK(SZ:000931)2022-12-06 11:31Group 1: Company Overview and Business Structure - Beijing Zhongguancun Science and Technology Development (Holding) Co., Ltd. focuses on the pharmaceutical and health industry, with a strategic shift towards "big health" as its core business [11][12] - The company has two research and development centers, three production bases, and three sales teams [3][4] Group 2: Research and Development Progress - The company has obtained 12 production approvals, including various drug categories, and has made significant advancements in clinical trials and patent applications [3][4][6] - Current R&D projects include pain management drugs and anti-fungal agents, with a focus on enhancing product lines and meeting market demands [6][7][8] Group 3: Sales and Market Performance - The OTC and health product division has established a strong market presence, with over 1,000 retail outlets and hospitals engaged by the end of April 2016 [4][5] - The company’s prescription drug division has seen a revenue growth of nearly 60% year-on-year, indicating robust market performance [5] Group 4: Future Business Development Plans - The company plans to execute at least two merger and acquisition projects annually, focusing on expanding its pharmaceutical production capabilities and exploring opportunities in medical devices and healthcare services [12][13] - A new marketing strategy will be implemented to enhance sales team engagement and operational efficiency [13] Group 5: Production and Talent Development - Plans to expand production capacity include building a new production line for tablets and establishing a sterile production facility to meet regulatory requirements [14][15] - The company aims to enhance its workforce by recruiting skilled professionals and implementing an incentive program to align employee goals with corporate strategy [15] Group 6: Non-Pharmaceutical Asset Management - The company holds over 1 billion CNY in non-pharmaceutical assets, with a focus on divesting non-core assets to strengthen its pharmaceutical business [16]